DD of a clinical stage therapeutic for rare neurodegenerative disorders

Challenge: A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate...
Learn More

Ongoing Due Diligence Support

Challenge: A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a...
Learn More

Commercial supply chain for US launch of a blood cancer drug

Challenge: Our client was a publicly-traded clinical-stage biopharmaceutical company using an epigenetic approach modulate gene expression in tumor and immune cells to treat cancer. Their lead...
Learn More

Due Diligence of Late Stage Gene Therapy Asset

Challenge: Our client, a global pharmaceutical company, was facing a short deadline to making an offer for a late stage gene therapy asset and was under considerable competitive deal pressure. This...
Learn More

Landscape Analysis of the Radiopharma Market

Challenge: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of...
Learn More

Pharmaceutical Licensing: Negotiation Support

Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...
Learn More
Content not found